

REMARKS

Claims 1-14 are pending in the application. The specification has been amended to identify the primer sequences at pages 13, 14, and 21 in the specification by the corresponding SEQ ID NOS according to the substitute Sequence Listing submitted herewith. Accordingly, no new matter has been inserted into the application.

Submission of Sequence Listing

In response to Withdrawal of Previously Sent Notice and Notification of Defective Response dated March 1, 2006 indicating that the above-identified application does not comply with the sequence rules because the nucleotide sequences appearing on pages 12, 13, 14, and 20 in the published international application number PCT/KR2003/001308, filed July 2, 2003 with publication number WO 2004/005343 A1 do not have SEQ ID NOS, enclosed herewith in full compliance with 37 C.F.R. §§ 1.821-1.825 is a Sequence Listing to be inserted into the specification. The Sequence Listing in no way introduces new matter into the specification.

Also submitted herewith in full compliance with 37 C.F.R. §§ 1.821-1.825 is a computer readable disk copy of the Sequence Listing. Applicant's undersigned representative hereby states that the information recorded in computer readable form is identical to the written sequence listing.

Preliminary Amendment

Amendments to the Specification have been made in accordance with the substitute Sequence Listing inserting new SEQ ID NOS:3-5 to identify the nucleotide sequences without the SEQ ID NOS on pages 13, 14, and 21 in the specification as filed on January 3, 2005 by the appropriate SEQ ID NOS. The Examiner's attention is drawn to the fact that only the underlined

Serial No.
10/520,258

Patent
20050-00003

SEQ ID NOS are the text with the desired change in the Amendments to the Specification.

However, please note that the underlined nucleotide sequences are as originally presented and not intended to indicate the desired change in the text.

The Commissioner is authorized to charge JHK Law's Deposit Account No. 502486 for any fees required under 37 CFR §§1.16 and 1.17 and to credit any overpayment to said Deposit Account No. 502486.

March 28, 2006

Respectfully submitted,

Handwritten signature of Joseph Hyosuk Kim, with the text "Reg. No. 56,814" written next to it.

Joseph Hyosuk Kim, Ph. D.
Registration No. 41,425

JHK Law
P.O. Box 1078
La Canada, CA 91012-1078
Telephone: 818-249-8177
Facsimile: 818-249-8277



PAGE: 1
03/28/2006

VERIFICATION SUMMARY REPORT

DATE:

PATENT APPLICATION

TIME:

11:38:05

INPUT SEQ: C:\Documents and Settings\Joseph
Kim\My Documents\JHK Law Documents\Patent Applications\20050 - SeShin
\20050-00003\20050-00003.ST25.txt

GENERAL INFORMATION SECTION

3,<110> NEXGEN BIOTECHNOLOGIES, INC.
4, SHONG, Min-Ho
5, LEE, Sun
6, YOO, Jae-Geun
7, JIN, Seok-Min
9,<120> Production of Transformed Plants Expressing Thyroid
Stimulating
10, Hormone Receptor
12,<130> 20050-00003
14,<140> US 10/520,258
15,<141> 2005-07-21
17,<150> KR 2002-38064
18,<151> 2002-07-02
20,<150> PCT/KR2003/001308
21,<151> 2003-07-02
23,<160> 5
25,<170> PatentIn version 3.3

ERRORED LINES SECTION

STATISTICS SUMMARY

Application Serial Number: US 10/520,258
Alpha or Numeric or Xml: Numeric
Application Class:
Application File Date: 2005-07-21
Art Unit:
Software Application: PatentIN3.3
Total Number of Sequences: 5
Total Nucleotides: 2368
Total Amino Acids: 763
Number of Errors: 0
Number of Warnings: 0
Number of Corrections: 0